A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma

Summary

The purpose of this study was to assess the effect of tasisulam as an inhibitor of CYP2C9, using tolbutamide as a probe substrate. This study was to have 3 treatment periods, and continued access in an extension period. Period 1 is 4 days in length. Periods 2 and 3 are each approximately 28 days in length. Due to the early termination of the trial, only 1 Period 3 participant enrolled in the extension period before study termination.

Timeline

Start

2010-07

Primary completion

2010-12

Completion

2010-12

Drugs

Indications